Erratum: The interleukin-1 balance is associated with clinical severity, blood-brain barrier permeability, neuroimaging changes and outcome in encephalitis (Journal of Infectious Diseases (2015) 213 (1651-1660) DOI: 10.1093/infdis/jiv771);The Interleukin-1 Balance during Encephalitis Is Associated with Clinical Severity, Blood-Brain Barrier Permeability, Neuroimaging Changes, and Disease Outcome

Journal of Infectious Diseases

Volumn 213, Issue 10, 2016, Pages 1651-1660

  Michael, Benedict Daniel ^a,b   Griffiths, Michael J ^a,c   Granerod, Julia ^d   Brown, David ^d,f   Keir, Geoff ^b   Wnȩk, Gosia ^a   Cox, Daniel J ^e   Vidyasagar, Rishma ^e   Borrow, Ray ^d   Parkes, Laura M ^e   Solomon, Tom ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Blood brain barrier; Chemokine; Cytokine; Encephalitis; Herpes simplex

Indexed keywords

ALBUMIN; BETA INTERFERON; CELL ADHESION MOLECULE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE 1; ALBUMINOID; AUTACOID; IL10 PROTEIN, HUMAN; SERUM ALBUMIN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; BACTERIAL INFECTION; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CORRELATION ANALYSIS; CRYPTOCOCCOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENCEPHALITIS; GLASGOW COMA SCALE; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLUENZA A; MAJOR CLINICAL STUDY; MEASLES; MEMBRANE PERMEABILITY; MIXED INFECTION; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TOXOPLASMOSIS; TUBERCULOSIS; VARICELLA ZOSTER VIRUS; VASCULITIS; BLOOD; CAPILLARY PERMEABILITY; CEREBROSPINAL FLUID; CLINICAL TRIAL; COHORT ANALYSIS; ENGLAND; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; SIMPLEXVIRUS;

ALBUMINS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; COHORT STUDIES; ENCEPHALITIS, HERPES SIMPLEX; ENGLAND; GLASGOW COMA SCALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-1BETA; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; PROSPECTIVE STUDIES; SERUM ALBUMIN; SIMPLEXVIRUS; TEMPORAL LOBE;

EID: 84969988630     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix218     Document Type: Erratum

References (49)

1. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144-9.
2. Solomon T, Michel BD, Smith PE, et al. Management of suspected viral encephalitis in adults: Association of British Neurologists and British Infection Association National Guideline. J Infect 2012; 64:347-73.
3. Lokensgard JR, Hu S, Sheng W, et al. Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J Neurovirol 2001; 7:208-19.
4. Ichiyama T, Shoki H, Takahashi Y, et al. Cerebrospinal fluid levels of cytokines in non-herpetic acute limbic encephalitis: comparison with herpes simplex encephalitis. Cytokine 2008; 44:149-53.
5. Kamei S, Taira N, Ishihara M, et al. Prognostic value of cerebrospinal fluid cytokine changes in herpes simplex virus encephalitis. Cytokine 2009; 46:187-93.
6. Wright JL, Merchant RE. Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-alpha in the rat. J Neurooncol 1994; 20:17-25.
7. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001; 54:329-38.
8. Saxena V, Mathur A, Krishnani N, et al. An insufficient anti-inflammatory cytokine response in mouse brain is associated with increased tissue pathology and viral load during Japanese encephalitis virus infection. Arch Virol 2008; 153:283-92.
9. Saxena V, Mathur A, Krishnani N, et al. Kinetics of cytokine profile during intraperitoneal inoculation of Japanese encephalitis virus in BALB/c mice model. Microbes Infect 2008; 10:1210-7.
10. Alheim K, Bartfai T. The interleukin-1 system: receptors, ligands, and ICE in the brain and their involvement in the fever response. Ann N Y Acad Sci 1998; 840:51-8.
11. Dietrich WD, Busto R, Bethea JR, et al. Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Exp Neurol 1999; 158:444-50.
12. Boutin H, Kimber I, Rothwell NJ, Pinteaux E. The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain? Mol Neurobiol 2003; 27:239-48.
13. Vitkovic L, Maeda S, Sternberg E, et al. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation 2001; 9:295-312.
14. Winter PM, Dung N, Loan HT, et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis 2004; 190:1618-26.
15. Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus. Virol J 2005; 2:59.
16. Conrady CD, Drevets DA, Carr DJ. Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing? J Neuroimmunol 2010; 220:1-9.
17. Granerod J, Ambrose H, Davies NWS, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10:835-44.
18. Marcotte TD, Deutsch R, Michael BD, et al. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol 2013; 8:1123-35.
19. Michael BD, Elsone L, Griffiths MJ, et al. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms-a pilot study. Cytokine 2013; 64:90-6.
20. Day NP, Hein TT, Schollaardt T, et al. The prognostic and pathophysiologic role of pro-and antiinflammatory cytokines in severe malaria. J Infect Dis 1999; 180:1288-97.
21. Reiber H. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem 1995; 41:256-63.
22. Demaerel P, Wilms G, Roberecht W, et al. MRI of herpes simplex virus. Neuroradiol 1992; 34:490-3.
23. Mackay CE, Webb JA, Eldridge PR, et al. Quantitative magnetic resonance imaging in consecutive patients evaluated for surgical treatment of temporal lobe epilepsy. Magn Reson Imaging 2000; 18:1187-99.
24. Hallan BP, Craig MC, Toal F, et al. In vivo brain anatomy of adult males with Fragile X syndrome: an MRI study. Neuroimage 2011; 54:16-24.
25. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135-60.
26. Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology 2007; 46:417-25.
27. Griffiths MJ, Ooi M, Wong SC, et al. In enterovirus 71 encephalitis with cardiorespiratory compromise, elevated interleukin 1beta, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. J Infect Dis 2012; 206:881-92.
28. Kennedy PG. Viral encephalitis. J Neurol 2005; 252:268-72.
29. Tunkel AR, Glase CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303-27.
30. Raschilas F,Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis 2002; 35:254-60.
31. Rosler A, Pohl M, Braune HJ, et al. Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. J Neurol Sci 1998; 157:82-9.
32. Emsley HC, Smith C, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76:1366-72.
33. Burton JM, O'Connor PW, Hohol M, et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12:CD006921.
34. Gibson RM, Rothwell N, Le Feuvre RA. CNS injury: the role of the cytokine IL-1. Vet J 2004; 168:230-7.
35. Tse MC, Lane C, Mot K, et al. ICAM-5 modulates cytokine/chemokine production in the CNS during the course of herpes simplex virus type 1 infection. J Neuroimmunol 2009; 213:12-9.
36. Aurelius E, Ansersson B, Forsgren M, et al. Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis. J Infect Dis 1994; 170:678-81.
37. Sergerie Y, Rivest S, Boivin G, et al. Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis. J Infect Dis 2007; 196:853-60.
38. Salliot C, Dougados M, Gossec L, et al. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25-32.
39. Furlan R, Bergami A, Brambilla E, et al. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2007; 14:93-8.
40. Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 2009; 106:4355-9.
41. Upton AR, Foster JB, Barwick DD. Dexamethasone treatment in herpes-simplex encephalitis. Lancet 1971; 1:861.
42. Kamei S, Sekizawa T, Shiota H, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 2005; 76:1544-9.
43. Meyding-Lamade UK, Oberlinner C, Rau PR, et al. Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J Neurovirol 2003; 9:118-25.
44. Marques CP, Hu S, ShengW, CheeranMC, et al. Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia. Glia 2004; 47:358-66.
45. Molina-Holgado E, Arevalo-Martin A, Ortiz S, et al. Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci Lett 2002; 324:237-41.
46. Labus J, Hackel S, Lucka L, et al. Interleukin-1beta induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain model. J Neurosci Methods 2014; 228:35-45.
47. Wilson EH, Wille-Reece U, Dzierszinski F, et al. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J Neuroimmunol 2005; 165:63-74.
48. Tumpey TM, Elner VM, Chen SH, et al. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. J Immunol 1994; 153:2258-65.
49. Ramakrishna C, Newo A, Shen YW, et al. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog 2011; 7:1002071.